Cohort studies have been central to the establishment of the known causes of cancer. To dissect cancer etiology in more detail, for instance for personalized risk prediction and prevention, assessment of risks of subtypes of cancer, and assessment of small elevations in risk, there is a need for analyses of far larger cohort datasets than available in individual existing studies.
Introduction
For over 60 years, since Doll & Hill (1) and Hammond & Horn (2) demonstrated the ill-effects of smoking, and Case et al (3) demonstrated the hazards of dyestuff manufacture to the bladder, cohort studies have been the principal method to provide definitive evidence of the carcinogenicity to humans of noxious agents, behaviors, and other exposures. Almost every cause of cancer that is known was established by this means (4) . Increasingly, however, the need to dissect cancer etiology in more detail, and to pursue risk factors with smaller effects, has meant that even the largest cohorts are proving to be too smallfor instance, to assess risks from uncommon exposures, or of uncommon types or subtypes of cancer, or to examine interactions or risks in population subgroups. The advent of molecular genetics, often examining very small elevations or decreases in risk, and of personalized risk prediction, examining risks subdivided across multiple susceptibility strata, have exacerbated the problem.
Existing cohorts, however, have tended to be limited in size by financial and practical constraints. They have frequently been recruited from a restricted subset of the population, for instance teachers (5) or nurses (6, 7) , and, with notable exceptions such as the Multiethnic Cohort Study (8) , have often been limited in ethnic diversity.
Similarly, cancer-focused cohorts, with some exceptions (e.g. (5-7, 9, 10) ), have tended to recruit study participants who were at least 35 years of age at baseline, to increase the numbers of incident cancers early in follow-up. Furthermore, study investigators have focussed most of their energy on their cohort's areas of research strength. Consequently, questionnaire data and biospecimens from these cohorts have often remained unused (or if used, greatly underpowered) for analyses that require larger numbers.
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Author Manuscript Published OnlineFirst on July 17, 2018; DOI: 10.1158/1055-9965.EPI- One potential solution to this problem has been to assemble ever-larger new cohorts (11, 12) , but there are practical and financial limitations to the size of these, and new cohorts take many years before they accrue sufficient follow-up and outcome events.
They have also tended to be of limited diversity by age, sometimes by sex, and usually by ethnicity and country. Pooling data from existing cohorts internationally can relatively cheaply and quickly provide cohort data on a very large scale, with diversity of populations and exposures, capitalizing on the investments already made in such cohorts and their follow-up.
Foundation of the Cohort Consortium, and its initial objectives
To address these challenges, and to exploit new opportunities such as advances in methods for molecular genetics, the US National Cancer Institute (NCI), led by Drs.
Robert Hoover and Robert Hiatt, convened a meeting in 2001 with the principal investigators of several cancer epidemiology cohorts. The meeting was embedded in a wider strategy that NCI developed in relation to genetic risk factors, cancer risks, and strategies for prevention.
These investigators agreed on the value of pooling projects to enable analyses that no one cohort, nor even a few cohorts in alliance, could do alone, while still allowing the individual cohorts to meet their own scientific objectives. Another contributor to the ethos was the Pooling Project of Prospective Studies of Diet and Cancer (13) , started in 1991, which includes many of the studies within the Consortium, and now forms a Working Group within it. The NCI therefore created the Cohort Consortium, initially fostering within it the Breast and Prostate Cancer Cohort Consortium (BPC3) (14) , which examined risks of breast and prostate cancers, using a nested casecontrol design within each of nine cohorts. BPC3 initially assessed risks in relation to germline variants in more than 60 candidate genes related to steroid hormone Research.
Author Manuscript Published OnlineFirst on July 17, 2018; DOI: 10.1158/1055-9965.EPI- metabolism and the IGF pathway (15) (16) (17) with greater precision than previously available and then, taking advantage of the rapidly declining costs of genomic assays, conducted a series of genome-wide association studies (GWAS) of these cancers (18, 19) . The infrastructure and collaborative trust built up over time were central to the success of these GWAS.
Structure and operations of the Consortium
The Consortium has since grown greatly in size and scope. It now comprises over 200 scientists from multiple institutions internationally, who have agreed to participate in collaborative research efforts and to pool data from their cohorts to address scientific questions that cannot otherwise be addressed through single institutions and cohorts.
Governance and leadership
The Consortium's bylaws (https://epi.grants.cancer.gov/Consortia/bylaws.html) describe its current overall governance structure and the roles and responsibilities of the steering committee, Consortium members, and NCI staff, and are designed to facilitate dynamic, collaborative research, for instance by frequent rotations of the steering committee membership, and by each cohort having one vote on matters related to the Consortium.
The Consortium activities are overseen by a steering committee elected by the members. The steering committee is responsible for policy development, management, and setting the scientific direction. It includes 6-9 principal investigators who reflect the institutional, geographic and gender diversity of the member cohorts, and three NCI ex-officio voting members representing the NCI
Divisions of (i) Cancer Control and Population Sciences and (ii) Cancer
Epidemiology and Genetics. The chair and chair-elect are elected by the steering committee. Steering committee members are appointed for up to three three-year terms, and the chair for a one-year term. The overall day-to-day operations and technical support are managed by four NCI Executive staff.
The steering committee holds monthly teleconferences to monitor the progress of ongoing Consortium studies and projects, address problems that arise in those projects, assess proposals for new scientific research projects and working groups, and organize the annual meeting.
Membership
There are currently 58 epidemiological cohorts in the Consortium, representing populations from 20 countries across four continents (North America, Europe, Asia, and Australia). Membership of the Consortium is open, on application, to any cohort study with a minimum of 10,000 participants, in which cancer incidence is accurately assessed and some risk factor data are available. Membership also requires a general commitment to scientific collaboration through contribution of data for pooling research, but for each specific pooling project, individual cohorts decide freely whether or not they wish to participate. Membership is granted after a review of the application and a vote of the steering committee.
Annual meetings
The Consortium members meet annually in person to review progress, gain updates on ongoing and new projects, discuss new research ideas, share study results, and address methodological challenges. The content of the annual meetings is decided by the steering committee and the practical organisation is by the NCI Leadership Staff. The meetings last 2-3 days, and include: talks by some individual working groups, reporting on their progress; talks on scientific methodology or on areas, e.g.
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Author Manuscript Published OnlineFirst on July 17, 2018; DOI: 10.1158/1055-9965.EPI-18-0182 metabolomics, that have potential for use in cohort epidemiology; and interactive sessions about the working of the Consortium. In addition the annual meetings provide a forum for individual Consortium working groups to meet to progress their pooling research. Such working group meetings may be open to all attending the Consortium meeting, or limited to cohorts participating in the working group, for instance because confidential new results are to be shown, including cohort-specific results from cohorts that have not yet published their own data separately.
Working groups and new research projects
The collaborative research in the Consortium is conducted by investigator-led working groups, of which there are currently more than 40. The steering committee assesses proposals monthly for new projects and hence for new working groups.
Proposals from non-members are evaluated on the same basis as those from members of the Consortium. The proposals are made on a standard form that captures the rationale, design and proposed funding sources for the intended research, and practical details such as the minimum number of incident cancers that will be required for a cohort to join the particular pooling study. Each proposal is evaluated by the Consortium steering committee, based on the need for prospectively collected data/samples pooled from multiple cohorts, whether there is overlap or duplication of efforts by existing working groups, and the project's potential to make a novel contribution to scientific research and public health. Initial appraisal frequently leads to a request to the proposer for clarification or further information, with the intention to improve the clarity of the proposal to individual cohort members of the consortium and hence improve the chance that these cohorts will take part. The great majority of proposals are either then accepted by the steering committee to be disseminated to members as new working groups, or directed toward joining an existing working group as a sub-project. Although approval by the steering committee is required for a new working group to be formed, decisions on subsequent research or spin off projects within an existing working group are the responsibility of the group itself.
Once a working group is formed, participation of cohorts in the group is solicited by an email from the steering committee to members, and then direct communication by the lead investigator. The great majority of working groups go on to conduct and publish research successfully, but occasionally one does not, because the research proves to be infeasible (e.g. there are fewer cases than had been anticipated), or too few investigators choose to join, or the researchers have not been able to obtain funding.
Communications
A growing, large scale international consortium of this kindrequires effective and efficient bi-directional communication to maximize collaborations and productivity. A news letter, including information on new projects, is sent to Consortium members monthly. Webinars are used to host virtual meetings of working groups, as well as in conjunction with the in-person annual meetings to include members who cannot attend. Working groups provide regular progress updates on their projects to the steering committee in conference calls, to discuss accomplishments, challenges, lessons learned and suggestions to improve the working of the consortium. They also share their study results through oral and poster presentations at the annual meeting.
A secure portal, with access limited to consortium members, has been created to foster collaboration and information sharing. The portal serves as a repository and archive for all consortium related activities including concept proposals, operational guidelines, historical documents and best practice documents, and is used by the scientific working groups for research activities. Individual working groups and projects are able to set up private work spaces within the portal with access limited to members of that working group. Several, but not all, working groups have used the portal in varying capacities for sharing updates, study policies and protocols, data, and manuscript versions, among their members. funding (especially for laboratory assays) will not cover further cohorts joining; or that adding further cohorts, and the data transfer agreements and data harmonization entailed, would seriously delay analyses already well underway.
Current Consortium projects and working groups

Operations and organization
The organization of individual projects and working groups varies. Most are led by the proposing investigator(s). Sometimes a steering committee is formed to manage activities and help with decision-making. The structure of working groups has varied widely. Some, for instance, have extensive written ground rules, publication guidelines, etc., while other are informal with no written rules. Some have continued for 10 years or more, accruing new analyses and purposes over time, while others have been formed for and conducted a specific investigation (e.g. a particular assay), published it, and disbanded. It is a strength of the Consortium that the collaborative arangements for working groups are flexible and in the hands of the members of each working group; additionally since most cohorts are members of many working groups, there is a great deal of expertise and experience from previous working groups to be drawn upon when creating new ones.
The Consortium supports the development of the next generation of cancer epidemiology researchers by encouraging junior investigators to assume leadership and other active roles in managing Consortium studies, for instance as leaders of spin-off projects. Funding for projects varies, as described below. providing limited administrative resources. To facilitate data sharing and data harmonization the NCI has funded the Cancer Epidemiology Descriptive Cohort Database (CEDCD) (https://cedcd.nci.nih.gov/), and two data repositories, the Cohort Metadata Repository (CMR) (https://cmr.nci.nih.gov/) and the Cancer Epidemiology Data Repository (CEDR) (https://epi.grants.cancer.gov/CEDR/), described in Table 1 . The CEDCD allows investigators to search for the types of data and biospecimen that were collected by each cohort study, numbers of cohort participants and numbers of incident cancers, in order that investigators planning a consortium project can determine which cohorts have data on the specific variables of interest and potential numbers of subjects and cancers that might be available.
Details of the working groups and their accomplishments can be found on the
The CMR is a tool that documents data harmonization processes, decisions and harmonized variables across cohorts that are participating in Consortium studies. It does not include individual-level data. Researchers interested in conducting pooled analyses in the consortium can view these metadata, including harmonized variables from specific projects and the specifications used to create them, to determine if they could use already-harmonized data sets for their analyses instead of undertaking a separate time-consuming harmonization effort.
The CEDR is a controlled acess database developed to enable sharing of actual research data, while protecting the privacy of research participants. Researchers can deposit, access, and analyze a variety of individual-level de-identified data, ensuring that use aligns with specific data use agreements and informed consent for each study.
Description of the participating cohorts
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The cohorts taking part in the Consortium are shown in Table 2 . They are contributing data from more than nine million study participants, and biospecimens, including germline DNA collected at baseline, from approximately 2 million participants.
The majority (60%) of the cohorts are entirely or predominantly US-based, two are from Canada, 13 from Europe, six from south-east Asia, and one each from Mexico, Australia and Iran. Most (66%) studies have less than 100,000 participants (40% less than 50,000 and 14% less than 20,000), 16 Twenty-eight cohorts were established to investigate multiple causes of cancer, five of these for specific cancers only; the remainder aimed also to investigate other diseases or causes of death. Eight cohorts had as their primary aim to assess the influence of diet on cancer and/or other diseases, and ten others focused on vitamins, minerals or other medications as potential preventative agents for cancer.
Other cohorts were established to investigate specific risk factors such as radiation, exogenous sex hormones and genetics.
Base populations.
The cohorts were recruited using a variety of sampling strategies and target populations ( Table 2 ). The largest group of cohorts were sampled from geographic regions or countries, several were from occupational groups, and 10 were leveraged Outcome ascertainment.
All cohorts in the Consortium follow participants for cancer incidence, with the majority linking to cancer registries and/or using regular follow-up questionnaires or telephone calls. Self-reported cancers are generally validated through medical or pathology record review. To follow for overall mortality or cause of death, some cohorts link to existing data sources such as national, state or county death registries, or medical records; some also use active follow-up for these purposes. one or two centers. While the NCI has on occasion conducted harmonization of the database and/or the statistical analyses for specific projects, these tasks have mostly been carried out by members of the working groups themselves, with the procedures then re-used for any further pooled projects within the working group. The Consortium has not in the past had a central data repository; members have generally preferred to provide data sets from their cohorts to the team conducting the analysis, rather than to a central entity. However, NCI has recently instituted a controlled-access repository, the CEDR, described above, where investigators can deposit individual-level de-identified data, to make their data more readily accessible by others and avoid having to respond to repeated data requests.
Several of the US cohorts including the VITamins and
Data harmonization is frequently highlighted by Consortium investigators as a major bottleneck, and one for which the workload tends to be underestimated. Questions and response categories for a particular exposure often differ between cohorts, and when harmonizing the data the exposure categories may have to be limited to fewer categories in common.
The ease or difficulty of harmonization relates closely to the complexity, and degree of variety between studies, in the questions about, as well as the recording of, the risk factors. Relatively simple risk factors such as height and weight, tend to be relatively easy to harmonize, but even these can be problematic e.g. weights can be at different ages and because recording may have grouped weight into different, 
Financial aspects
Obtaining sustained funding to maintain existing cohorts can itself be a major challenge, but without this, cohorts have limited capacity to contribute to a single, let alone multiple, consortial projects.
Setting up a new Consortium project also involves costs, both for the coordinating group and to a lesser extent for each participating cohort. While "data only" studies have sometimes been realized on a relatively slim or no budget by leveraging existing resources, studies involving assays of biological samples are inevitably costly. Retrieving biospecimens from cohort biobanks, preparation of aliquots, shipping, and performing the relevant assays is expensive, and biomarker-based consortium studies have typically required substantial grants.
When grants are obtained, these frequently include a small amount of support to each participating cohort, for instance, for preparation of the study database. NCI has developed and funded certain targetted initiatives within the Cohort Consortium to address NCI high programmatic and scientific research needs, but usually funding for projects has been obtained from investigator-initiated grants, from NCI or other sources. In the 171 published Consortium papers that stated funding sources, all but 2 cited the US NCI as a source (but this can include support of individual cohorts, not just the overall pooling) and 30 cited other US NIH Institutes, especially the National Institute on Aging [22] and the National Institute of Environmental Health Sciences [14] , while the American Cancer Society contributed to funding of 43. Three quarters of the papers cited funding solely from the US, and a tenth by 3 or more countries.
Cohort consortium publications
Research. The vast majority of the papers [159 [85%]] were on cancer epidemiology (Table 3) , mainly focussing on associations between genetic (51%) or lifestyle/anthropometric (27%) risk factors and cancer incidence [155] or less often for cancer survival [4] or cancer mortality [2] . These were mainly of nested case-control or cohort design, but in some instances also included non-cohort-based case-control studies to maximize numbers, for instance for genetic analyses ( Table 4 ). The remainder of the papers covered epidemiology of other outcomes including mortality (most commonly allcause mortality) (4%), biomarkers (2%), mechanisms including DNA methylation and mosaicism (3%), and methodology for pooling projects (7%). Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2018; DOI: 10.1158/1055-9965.EPI-18-0182 environment interactions [8] , or addition of genetics in risk models [4] . Studies of anthropometry, smoking and alcohol often found moderate associations with cancer risk, while studies of diet often gave less marked or null findings. A large number of studies examined the associations between pre-diagnostic biomarkers and cancer, most of which found no association with risk.
Although the majority of cohort participants overall are white, there are sufficient nonwhites that 6 papers were published solely on Chinese and 2 solely on African Americans, as well as 12 with analyses stratified by ethnic group.
Among the 159 cancer-related articles, the sites most frequently studied were breast (26%), prostate (22%) and pancreas (18%), but many papers also included less common sites (Table 3 ). In total, 67 of the papers were on cancers defined by the US National Cancer Institute as 'rare' (<15 cases per 100,000 per annum) and many of common cancers included subdivisions that require large numbers e.g. 17 papers on breast cancer subdivided by hormone receptor status, and papers on in-situ breast cancer and Type II endometrial cancer. The exposures analysed were in general relatively common (Table 3) , but again large numbers enabled investigation of uncommon subsets within these (e.g. there were 2 papers on risks in metabolically healthy obese subject), and of subdivisions by more than one variable e.g. lung cancer risks in relation to vegetable intake and smoking, and liver cancer risks in relation to OC use and oophorectomy. For genetics, the need for large numbers was to enable the search for the relatively small elevations in relative risk that are typically present for individual SNPs , thus necessitating pooling even for analyses of common cancers. Pooling successfully enabled analyses of large numbers of events, allowing greater power even for rare events than would have been possible in a single study. The average number of studies included in a manuscript was 10 and the average number of events was 7,026. There was a tendency for the publications on rarer cancers to include a larger number of studies and a smaller average sample size.
The average number of authors listed on the papers was 44, reflecting the team effort required for projects that combine studies; less than 15% of the papers had 15 or fewer authors. The Cohort Consortium offered opportunities to many researchers, including many junior investigators. One hundred and eighteen unique investigators were first authors on the 188 papers.
Conclusions
The Cohort Consortium has come a long way from a group of investigators from nine As a voluntary, investigator-led, collaborative framework, the future directions of the Consortium will depend on the wishes of its members. However, some general comments can be made. The opportunities that the Consortium has exploited, and will exploit in future, depend on funding constraints and incentives, the intrinsic strengths and limitations of the component cohorts, scientific opportunities and priorities, and the research interests of the members. Thus, for instance, there were many more gene-environment interactions, uncommon exposures and uncommon cancers that the Consortium could address in future, although the latter has the difficulty of a lack of funding opportunities, (e.g. site-specific charities for common cancers such as breast tend to be much better resourced than those for rarer tumors). Furthermore, for very rare cancers or subtypes of cancers, even a consortium of this size may contain too few cases to generate precise risk estimates.
The exposures that can be investigated with large numbers are limited to those for The Consortium needs to continue to expand, both to increase numbers for analyses of interactions, subgroup analyses and rare tumors and exposures, and to include more non-white populations, to enable larger analyses for these groups for which numbers within the Consortium are currently much fewer than for whites. The Consortium also needs to consider how to encourage and enable research on questions that currently are not addressed because no investigator has initiated investigation of the topic. Much of the 2017 annual meeting was spent discussing which research directions (e.g. rare tumors, rare exposures, gene-environment interactions) should be given priority in the next 5 years, and the steering committee is now formulating plans to address the priority areas.
Author Manuscript Published OnlineFirst on July 17, 2018; DOI: 10.1158/1055-9965.EPI- There is great potential for the Consortium to contribute to future research, with opportunities provided by the wealth and growing volume of data and biospecimens available from the underlying cohorts, the changing landscape of cancer risk factors within and across populations (e.g., the growing worldwide obesity epidemic), and the extraordinary technological advances occuring in the assessment of genetic, metabolomic, and other molecular characteristics. The large sample sizes of the Consortium are advantageous both for discovering novel associations and for validating findings from individual studies. The move towards precision medicine and prevention (30, 31) will need reliable, stable risk estimates from cohort studies in ever-finer subdivisions of the population. As noted above, large cohort-based databases will also be needed to investigate rare cancers, rare exposures, and gene-environment interactions, to stratify risks by tumor subtypes, and to refine population-level and individual-level risk prediction. There are also great opportunities in survivorship research, and in biomarker research. The Consortium welcomes new members with cancer-oriented cohorts of 10,000 or more participants and an interest in collaborative research. Cancer Epidemiology Data Repository CEDR Controlled access* Investigators will be able to deposit individual-level deidentified non-genomic data from observational cancer epidemiology datasets. Datasets can be updated with follow-up information on cancer incidence and mortality and could be individually linked to genomic data in NIH's database of Genotypes and Phenotypes (dbGaP).
* Since the Consortium is a voluntary pooling by cohorts from many countries, that need to meet their local legal, ethics and fundermandated policies on subject privacy and data sharing, as well as meeting the signed consent and participant information constraints of their cohort-specific recruitment, these consortial databases are restricted or controlled access. Table. b Not included separately when counting numbers of cohorts in the text, because it is a subset of another cohort in this Table. c Overall RERF cohort is 197,000, but 53,000 of these are suitable and potentially available for consortial pooling. 
